Lenalidomide and Cetuximab in Treating Patients With Metastatic Colorectal Cancer
Status:
Terminated
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Lenalidomide may stop the growth of tumor cells by blocking blood flow to the
tumor. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways.
Some block the ability of tumor cells to grow and spread. Others find tumor cells and help
kill them or carry tumor-killing substances to them. Giving lenalidomide together with
cetuximab may kill more tumor cells.
PURPOSE: This phase I trial is studying the side effects and best dose of lenalidomide when
given together with cetuximab in treating patients with metastatic colorectal cancer.